moxonidine has been researched along with Diabetes Mellitus, Adult-Onset in 11 studies
moxonidine: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the anti-hypertensive and metabolic effects of moxonidine, a selective imidazoline II-receptor agonist that lowers BP by central inhibition of the sympathetic nervous system, and moxonidine plus the angiotensin II-receptor blocker irbesartan in patients with type 2 diabetes mellitus and mild hypertension." | 9.12 | Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. ( Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Salvadeo, S, 2007) |
| "Moxonidine is useful and safe for controlling arterial hypertension in obese patients." | 9.11 | Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. ( Abellán, J; de Vinuesa, SG; García-Galbis, JA; Hernández-Menárguez, F; Leal, M; Luño, J; Martínez-Pastor, A, 2005) |
| "This study evaluated the anti-hypertensive and metabolic effects of moxonidine, a selective imidazoline II-receptor agonist that lowers BP by central inhibition of the sympathetic nervous system, and moxonidine plus the angiotensin II-receptor blocker irbesartan in patients with type 2 diabetes mellitus and mild hypertension." | 5.12 | Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. ( Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Salvadeo, S, 2007) |
| "Moxonidine is useful and safe for controlling arterial hypertension in obese patients." | 5.11 | Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. ( Abellán, J; de Vinuesa, SG; García-Galbis, JA; Hernández-Menárguez, F; Leal, M; Luño, J; Martínez-Pastor, A, 2005) |
| "To assess hypotensive efficacy and metabolic neutrality of moxonidine (physiotenz)--a selective agonist of imidasoline receptors--in patients with mild and moderate arterial hypertension (AH) associated with diabetes mellitus (DM) type 2." | 3.72 | [The role of hypersympathycotony in development of arterial hypertension in patients with metabolic syndrome: potential of pathogenetically sound therapy]. ( Ametov, AS; Demidova, TIu; Smagina, LV, 2004) |
| "Subjects with type 2 diabetes experience an increased cardiovascular morbidity and mortality, related to a high prevalence of hypertension, dyslipidemia, and obesity." | 2.71 | Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. ( Gödicke, J; Häring, HU; Helsberg, K; Jacob, S; Klimm, HJ; Rett, K, 2004) |
| "In another group of rats (hemodynamic group), radio frequency transmitters were implanted 1 week before starting the diet, and mean blood pressure, heart rate, and motor activity were continuously monitored at baseline and for 4 weeks after beginning drug exposure." | 1.30 | Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. ( Dananberg, J; Johnson, WT; Steinberg, MI; Yakubu-Madus, FE; Zimmerman, KM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balink, H | 1 |
| Hemmelder, MH | 1 |
| de Graaf, W | 1 |
| Grond, J | 1 |
| Minushkina, LO | 1 |
| Trusov, VV | 1 |
| Aksenov, KV | 1 |
| Jacob, S | 1 |
| Klimm, HJ | 1 |
| Rett, K | 1 |
| Helsberg, K | 1 |
| Häring, HU | 1 |
| Gödicke, J | 1 |
| Abellán, J | 1 |
| Leal, M | 1 |
| Hernández-Menárguez, F | 1 |
| García-Galbis, JA | 1 |
| Martínez-Pastor, A | 1 |
| de Vinuesa, SG | 1 |
| Luño, J | 1 |
| Ametov, AS | 1 |
| Demidova, TIu | 1 |
| Smagina, LV | 1 |
| Derosa, G | 1 |
| Cicero, AF | 1 |
| D'Angelo, A | 1 |
| Fogari, E | 1 |
| Salvadeo, S | 1 |
| Gravina, A | 1 |
| Ferrari, I | 1 |
| Fassi, R | 1 |
| Fogari, R | 1 |
| Lazebnik, LB | 1 |
| Malichenko, SB | 1 |
| Serebrov, AN | 1 |
| Yakubu-Madus, FE | 1 |
| Johnson, WT | 1 |
| Zimmerman, KM | 1 |
| Dananberg, J | 1 |
| Steinberg, MI | 1 |
1 review available for moxonidine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
[Possibilities of the use of moxonidine in the treatment of arterial hypertension in patients with metabolic syndrome and diabetes].
Topics: Antihypertensive Agents; Biological Availability; Blood Pressure; Diabetes Mellitus, Type 2; Endothe | 2011 |
3 trials available for moxonidine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2004 |
Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Diabetes Mellit | 2005 |
Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Com | 2007 |
7 other studies available for moxonidine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Scintigraphic diagnosis of Erdheim-Chester disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Erdheim-Che | 2011 |
[Moxonidine is advantageous for hypertensive type 2 diabetic patients. Therapy of hypertension also lowers HbA1c].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycated Hemoglobin; H | 2003 |
[Effect of imidazoline receptor agonist moxonidine on the state of microcirculation and renal function in patients with hypertension and diabetes mellitus type 2].
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Hemodynamics; Hu | 2003 |
[The role of hypersympathycotony in development of arterial hypertension in patients with metabolic syndrome: potential of pathogenetically sound therapy].
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Male; | 2004 |
[Long-term antihypertensive therapy with moxonidine (cynt) in patients with insulin-independent diabetes mellitus].
Topics: Aged; Antihypertensive Agents; Cognition; Diabetes Mellitus, Type 2; Diuretics; Drug Evaluation; Dru | 1997 |
[The significance of the sympathetic nervous system during therapy for hypertension and related pathologies. Imidazoline-I1-receptor agonists. 17th Scientific Meeting of the International Society of Hypertension. Amsterdam, June 7, 1998].
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Humans; Hypertension; Imidazoles; Imidazoline Re | 1998 |
Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Circadian Rhythm; Diabetes Mellitus | 1999 |